BIOMAT Database Logo BIOMAT Database Logo

Letter: Bioavailability. 1974

D A Kavelman

UI MeSH Term Description Entries
D002170 Canada The largest country in North America, comprising 10 provinces and three territories. Its capital is Ottawa.
D003258 Consumer Behavior Behavior associated with the procurement of goods, services, or experiences. Consumer Preference,Consumer Satisfaction,Behavior, Consumer,Behaviors, Consumer,Consumer Behaviors,Consumer Preferences,Preference, Consumer,Preferences, Consumer,Satisfaction, Consumer
D004345 Drug Industry That segment of commercial enterprise devoted to the design, development, and manufacture of chemical products for use in the diagnosis and treatment of disease, disability, or other dysfunction, or to improve function. Industries, Pharmaceutic,Industry, Drug,Industry, Pharmaceutic,Industry, Pharmaceutical,Pharmaceutical Industry,Drug Industries,Industries, Drug,Industries, Pharmaceutical,Pharmaceutic Industries,Pharmaceutic Industry,Pharmaceutical Industries
D001702 Biopharmaceutics The study of the physical and chemical properties of a drug and its dosage form as related to the onset, duration, and intensity of its action. Pharmaceutics,Pharmaceutic

Related Publications

D A Kavelman
Letter: Drug bioavailability.
July 1976, Canadian Medical Association journal,
D A Kavelman
Letter: Digoxin bioavailability.
November 1973, Journal of the American Pharmaceutical Association,
D A Kavelman
Letter: Bioavailability of ampicillin.
October 1975, Journal of clinical pharmacology,
D A Kavelman
Letter: Bioavailability of folate.
March 1976, The American journal of clinical nutrition,
D A Kavelman
Letter: Bioavailability of erythromycin.
August 1973, The Medical journal of Australia,
D A Kavelman
Letter: Bioavailability of erythromycin.
August 1973, The Medical journal of Australia,
D A Kavelman
Letter: Bioavailability of phenytoin.
January 1976, Lancet (London, England),
D A Kavelman
Letter: Bioavailability--a problem in equivalence.
June 1975, Biometrics,
D A Kavelman
Letter: Improving the bioavailability of digoxin.
June 1975, Lancet (London, England),
D A Kavelman
Letter: Intravenous digoxin as a bioavailability standard.
January 1975, Clinical pharmacology and therapeutics,
Copied contents to your clipboard!